Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.
Status:
Recruiting
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
Patients with advanced cancers who have pleural effusion, especially those requiring pleural
evacuation, experienced poorer survival when treated with immunotherapy. The pleura also acts
as a natural barrier that can limit the penetration of immune checkpoint inhibitors. In this
multicenter phase 2 study, the preliminary efficacy and toxicity of intrapleural instillation
of the nivolumab in patients with immune-sensitive metastatic cancers will be accessed.